| scholarly article | Q13442814 |
| P50 | author | Tomáš Cihlář | Q88483170 |
| Anita Niedziela-Majka | Q110451091 | ||
| Roman Sakowicz | Q110451409 | ||
| P2093 | author name string | Christopher O'Sullivan | |
| Mini Balakrishnan | |||
| Stephen R Yant | |||
| Kirsten M Stray | |||
| Angela Tsai | |||
| Rujuta A Bam | |||
| Luong Tsai | |||
| P2860 | cites work | Transient and stable knockdown of the integrase cofactor LEDGF/p75 reveals its role in the replication cycle of human immunodeficiency virus | Q24538808 |
| LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration | Q24671948 | ||
| A tripartite DNA-binding element, comprised of the nuclear localization signal and two AT-hook motifs, mediates the association of LEDGF/p75 with chromatin in vivo | Q25255818 | ||
| Identification of a small-molecule binding site at the dimer interface of the HIV integrase catalytic domain | Q27630779 | ||
| Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication | Q27661671 | ||
| Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation | Q27677515 | ||
| The A128T Resistance Mutation Reveals Aberrant Protein Multimerization as the Primary Mechanism of Action of Allosteric HIV-1 Integrase Inhibitors | Q27677549 | ||
| Multimode, Cooperative Mechanism of Action of Allosteric HIV-1 Integrase Inhibitors | Q27678141 | ||
| New Class of HIV-1 Integrase (IN) Inhibitors with a Dual Mode of Action | Q27678745 | ||
| An essential role for LEDGF/p75 in HIV integration | Q28262502 | ||
| Identification of an evolutionarily conserved domain in human lens epithelium-derived growth factor/transcriptional co-activator p75 (LEDGF/p75) that binds HIV-1 integrase | Q28282487 | ||
| Raltegravir with optimized background therapy for resistant HIV-1 infection | Q28288290 | ||
| Large-scale functional purification of recombinant HIV-1 capsid | Q28487670 | ||
| Identification and characterization of the chromatin-binding domains of the HIV-1 integrase interactor LEDGF/p75. | Q30159754 | ||
| Requirement for integrase during reverse transcription of human immunodeficiency virus type 1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase. | Q30341397 | ||
| Role of PSIP1/LEDGF/p75 in lentiviral infectivity and integration targeting | Q33311290 | ||
| The lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication | Q33325927 | ||
| Pharmacophore-based discovery of small-molecule inhibitors of protein-protein interactions between HIV-1 integrase and cellular cofactor LEDGF/p75. | Q33476232 | ||
| An allosteric mechanism for inhibiting HIV-1 integrase with a small molecule | Q33488152 | ||
| Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers | Q33559015 | ||
| Role of human immunodeficiency virus type 1 integrase in uncoating of the viral core | Q33826918 | ||
| PD 404,182 is a virocidal small molecule that disrupts hepatitis C virus and human immunodeficiency virus | Q34074331 | ||
| LEDGF/p75-independent HIV-1 replication demonstrates a role for HRP-2 and remains sensitive to inhibition by LEDGINs | Q34186964 | ||
| Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication | Q34364648 | ||
| Integrase inhibitors to treat HIV/AIDS. | Q34397376 | ||
| A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. | Q50498229 | ||
| Inhibition of HIV type 1 infection with a RANTES-IgG3 fusion protein | Q77740538 | ||
| Discovery of inhibitors to block interactions of HIV-1 integrase with human LEDGF/p75 via structure-based virtual screening and bioassays. | Q34436597 | ||
| Discovery of a small-molecule HIV-1 integrase inhibitor-binding site | Q34772524 | ||
| Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication | Q35838477 | ||
| Virus-producing cells determine the host protein profiles of HIV-1 virion cores | Q36204700 | ||
| Blocking interactions between HIV-1 integrase and cellular cofactors: an emerging anti-retroviral strategy | Q36948784 | ||
| Integrase, LEDGF/p75 and HIV replication | Q37081043 | ||
| Integrase and integration: biochemical activities of HIV-1 integrase | Q37353201 | ||
| Relationships between infectious titer, capsid protein levels, and reverse transcriptase activities of diverse human immunodeficiency virus type 1 isolates | Q37568313 | ||
| Elvitegravir: a new HIV integrase inhibitor | Q37618489 | ||
| Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial | Q38375842 | ||
| The conserved set of host proteins incorporated into HIV-1 virions suggests a common egress pathway in multiple cell types | Q39190259 | ||
| Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication | Q39320408 | ||
| Small-molecule inhibitors of the LEDGF/p75 binding site of integrase block HIV replication and modulate integrase multimerization | Q39337204 | ||
| Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase | Q39902300 | ||
| Cell-free assays for HIV-1 uncoating | Q39914308 | ||
| Generation of high-titer pseudotyped retroviral vectors with very broad host range | Q40571115 | ||
| A quantitative assay for HIV DNA integration in vivo | Q40809319 | ||
| Interaction between human immunodeficiency virus type 1 reverse transcriptase and integrase proteins | Q40814997 | ||
| Endogenous reverse transcriptase assays reveal synergy between combinations of the M184V and other drug resistance-conferring mutations in interactions with nucleoside analog triphosphates | Q41037101 | ||
| LEDGF/p75 interacts with divergent lentiviral integrases and modulates their enzymatic activity in vitro | Q41844861 | ||
| Genetic analyses of conserved residues in the carboxyl-terminal domain of human immunodeficiency virus type 1 integrase | Q42091632 | ||
| In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor | Q42111140 | ||
| Symmetrical 1-pyrrolidineacetamide showing anti-HIV activity through a new binding site on HIV-1 integrase | Q46346735 | ||
| Integrase mutants defective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV-1 replication | Q46458488 | ||
| Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection | Q46466415 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e74163 | |
| P577 | publication date | 2013-01-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells | |
| P478 | volume | 8 |
| Q27728086 | A New Class of Allosteric HIV-1 Integrase Inhibitors Identified by Crystallographic Fragment Screening of the Catalytic Core Domain |
| Q34249167 | A critical role of the C-terminal segment for allosteric inhibitor-induced aberrant multimerization of HIV-1 integrase |
| Q90003787 | A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model |
| Q27683994 | A new class of multimerization selective inhibitors of HIV-1 integrase |
| Q40159851 | Allosteric HIV-1 Integrase Inhibitors Lead to Premature Degradation of the Viral RNA Genome and Integrase in Target Cells |
| Q40519415 | Allosteric HIV-1 integrase inhibitors promote aberrant protein multimerization by directly mediating inter-subunit interactions: Structural and thermodynamic modeling studies |
| Q27644578 | Allosteric Inhibition of Human Immunodeficiency Virus Integrase |
| Q91729766 | An Isoquinoline Scaffold as a Novel Class of Allosteric HIV-1 Integrase Inhibitors |
| Q92637590 | Block-And-Lock Strategies to Cure HIV Infection |
| Q54223780 | CLIP-related methodologies and their application to retrovirology. |
| Q27468669 | Capsid-Targeted Viral Inactivation: A Novel Tactic for Inhibiting Replication in Viral Infections |
| Q50126703 | Cellular and molecular mechanisms of HIV-1 integration targeting. |
| Q96952473 | Clinical targeting of HIV capsid protein with a long-acting small molecule |
| Q37616219 | Computational and synthetic approaches for developing Lavendustin B derivatives as allosteric inhibitors of HIV-1 integrase |
| Q37512925 | Critical Contribution of Tyr15 in the HIV-1 Integrase (IN) in Facilitating IN Assembly and Nonenzymatic Function through the IN Precursor Form with Reverse Transcriptase |
| Q39103603 | Different Pathways Leading to Integrase Inhibitors Resistance |
| Q27684242 | Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1 |
| Q27321347 | Distribution and Redistribution of HIV-1 Nucleocapsid Protein in Immature, Mature, and Integrase-Inhibited Virions: a Role for Integrase in Maturation |
| Q92623235 | Dominant Negative MA-CA Fusion Protein Is Incorporated into HIV-1 Cores and Inhibits Nuclear Entry of Viral Preintegration Complexes |
| Q27680666 | Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage |
| Q40457748 | Dynamic Oligomerization of Integrase Orchestrates HIV Nuclear Entry |
| Q89669108 | Epigenetic crosstalk in chronic infection with HIV-1 |
| Q64231598 | Establishment of latent HIV-1 reservoirs: what do we really know? |
| Q30407372 | HIV virions as nanoscopic test tubes for probing oligomerization of the integrase enzyme. |
| Q35761626 | HIV-1 Gag as an Antiviral Target: Development of Assembly and Maturation Inhibitors |
| Q35170009 | HIV-1 IN/Pol recruits LEDGF/p75 into viral particles |
| Q40561974 | HIV-1 Integrase Binds the Viral RNA Genome and Is Essential during Virion Morphogenesis |
| Q38380688 | HIV-1 integrase multimerization as a therapeutic target |
| Q64950510 | HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors. |
| Q64086928 | Impact of LEDGIN treatment during virus production on residual HIV-1 transcription |
| Q41735307 | Induced maturation of human immunodeficiency virus. |
| Q47554259 | Inhibitors of the integrase-transportin-SR2 interaction block HIV nuclear import |
| Q61813266 | Insight in HIV Integration Site Selection Provides a Block-and-Lock Strategy for a Functional Cure of HIV Infection |
| Q99602676 | Integrase-RNA interactions underscore the critical role of integrase in HIV-1 virion morphogenesis |
| Q28543396 | Integrated analysis of residue coevolution and protein structures capture key protein sectors in HIV-1 proteins |
| Q27681778 | Interrogating HIV integrase for compounds that bind- a SAMPL challenge |
| Q37035177 | LEDGIN-mediated Inhibition of Integrase-LEDGF/p75 Interaction Reduces Reactivation of Residual Latent HIV |
| Q38199193 | LEDGINs, non-catalytic site inhibitors of HIV-1 integrase: a patent review (2006 - 2014). |
| Q36691836 | Methods for the Analyses of Inhibitor-Induced Aberrant Multimerization of HIV-1 Integrase |
| Q40809010 | Minimizing the Contribution of Enterohepatic Recirculation to Clearance in Rat for the NCINI Class of Inhibitors of HIV. |
| Q92992903 | Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition |
| Q26795766 | Multifunctional facets of retrovirus integrase |
| Q37574479 | Multimodal mechanism of action of allosteric HIV-1 integrase inhibitors |
| Q92834245 | N-arylnaphthylamines as inhibitors of human immunodeficiency virus integrase - lens epithelium-derived growth factor interactions: theoretical studies |
| Q33797858 | Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor |
| Q37417514 | Quantitative evaluation of the antiretroviral efficacy of dolutegravir |
| Q41925654 | Resistance to pyridine-based inhibitor KF116 reveals an unexpected role of integrase in HIV-1 Gag-Pol proteolytic processing |
| Q28596842 | Retroviral DNA Integration |
| Q28073156 | Retroviral Integrase: Then and Now |
| Q34263719 | Small-molecule inhibitors of protein-protein interactions: progressing toward the reality |
| Q28554866 | Structural Basis for Inhibitor-Induced Aggregation of HIV Integrase |
| Q52673279 | Structure-function analyses unravel distinct effects of allosteric inhibitors of HIV-1 integrase on viral maturation and integration. |
| Q38983286 | TALEN knockout of the PSIP1 gene in human cells: analyses of HIV-1 replication and allosteric integrase inhibitor mechanism |
| Q40033857 | TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells |
| Q36922166 | The Competitive Interplay between Allosteric HIV-1 Integrase Inhibitor BI/D and LEDGF/p75 during the Early Stage of HIV-1 Replication Adversely Affects Inhibitor Potency |
| Q45325032 | The HIV-1 integrase-LEDGF allosteric inhibitor MUT-A: resistance profile, impairment of virus maturation and infectivity but without influence on RNA packaging or virus immunoreactivity. |
| Q35215018 | The allosteric HIV-1 integrase inhibitor BI-D affects virion maturation but does not influence packaging of a functional RNA genome |
| Q42932779 | The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro |
| Q34611548 | The mechanism of H171T resistance reveals the importance of Nδ-protonated His171 for the binding of allosteric inhibitor BI-D to HIV-1 integrase |
| Q57799661 | The role of integration and clonal expansion in HIV infection: live long and prosper |
Search more.